NHS Cost-Effectiveness Thresholds Boost Drug Ap...

By João L. Carapinha

January 12, 2026

Confirmation of Adjusted Cost-Effectiveness Thresholds for NHS Medicines Evaluations The UK's National Institute for Health and Care Excellence (
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
INFARMED Leadership Appointments: A New Era in Health Regulation and Expertise
Preparing for the EU Health Technology Assessment: Key Insights from the Upco...
Transforming EU Pharmaceutical Legislation: EMA’s Strategic Priorities ...
CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals
Translational Medicine Portugal: Driving Collaborative Innovations in Healthcare
Arexvy RSV Vaccine Expansion: Broader Access and Impact on Adult Health Outcomes
Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Co...
AI Governance Pharmaceuticals: Ensuring Ethical AI Integration in the Medicin...
NICE Approves Seven Digital Cardiac Rehabilitation Technologies for Enhanced ...
Repurposing Off-Patent Medicines: Insights from the EU Pilot Initiative